Charles River Laboratories International, Inc. $CRL Stock Position Lifted by Balefire LLC

Key Points

• Balefire LLC increased its stake in Charles River Laboratories (NYSE: CRL) by 39.4%, acquiring an additional 3,815 shares during the second quarter, bringing its total holdings to 13,494 shares valued at approximately $2.05 million.
• Charles River Laboratories recently reported earnings of $3.12 per share for the last quarter, exceeding expectations of $2.50, with revenue of $1.03 billion.
• Analysts have rated Charles River Laboratories with an average rating of "Hold", with six analysts suggesting a "Buy" rating and an average target price of $177.07.

Balefire LLC raised its holdings in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 39.4% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 13,494 shares of the medical research company's stock after acquiring an additional 3,815 shares during the period. Balefire LLC's holdings in Charles River Laboratories International were worth $2,047,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of CRL. Teacher Retirement System of Texas purchased a new stake in shares of Charles River Laboratories International in the 1st quarter valued at approximately $1,231,000. Mirae Asset Global Investments Co. Ltd. boosted its position in Charles River Laboratories International by 15.4% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,118 shares of the medical research company's stock valued at $952,000 after buying an additional 817 shares during the period. Janney Montgomery Scott LLC boosted its position in Charles River Laboratories International by 13.1% in the 1st quarter. Janney Montgomery Scott LLC now owns 44,500 shares of the medical research company's stock valued at $6,698,000 after buying an additional 5,148 shares during the period. GAMMA Investing LLC boosted its position in Charles River Laboratories International by 61.6% in the 1st quarter. GAMMA Investing LLC now owns 1,398 shares of the medical research company's stock valued at $210,000 after buying an additional 533 shares during the period. Finally, Concurrent Investment Advisors LLC acquired a new stake in shares of Charles River Laboratories International in the 1st quarter valued at $213,000. Institutional investors and hedge funds own 98.91% of the company's stock.

Analysts Set New Price Targets

CRL has been the topic of a number of analyst reports. Jefferies Financial Group upgraded shares of Charles River Laboratories International from a "hold" rating to a "buy" rating and raised their price objective for the company from $142.00 to $195.00 in a report on Tuesday, September 9th. Evercore ISI lifted their price target on shares of Charles River Laboratories International from $180.00 to $190.00 and gave the stock an "outperform" rating in a research note on Friday, August 8th. Citigroup upgraded shares of Charles River Laboratories International from a "neutral" rating to a "buy" rating and lifted their price target for the stock from $150.00 to $200.00 in a research note on Wednesday, July 9th. Wall Street Zen lowered shares of Charles River Laboratories International from a "strong-buy" rating to a "buy" rating in a research note on Sunday. Finally, JPMorgan Chase & Co. lifted their price target on shares of Charles River Laboratories International from $145.00 to $160.00 and gave the stock a "neutral" rating in a research note on Thursday, August 7th. Six equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Charles River Laboratories International currently has a consensus rating of "Hold" and a consensus target price of $177.07.

Charles River Laboratories International Trading Down 1.1%

Shares of Charles River Laboratories International stock traded down $1.67 during trading hours on Friday, hitting $155.32. The company's stock had a trading volume of 1,280,048 shares, compared to its average volume of 774,769. The business has a fifty day moving average of $160.27 and a 200 day moving average of $148.32. The company has a market capitalization of $7.64 billion, a PE ratio of -116.78, a P/E/G ratio of 4.15 and a beta of 1.47. Charles River Laboratories International, Inc. has a 1-year low of $91.86 and a 1-year high of $230.02. The company has a quick ratio of 1.10, a current ratio of 1.36 and a debt-to-equity ratio of 0.69.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The medical research company reported $3.12 EPS for the quarter, beating analysts' consensus estimates of $2.50 by $0.62. The firm had revenue of $1.03 billion for the quarter, compared to the consensus estimate of $983.76 million. Charles River Laboratories International had a negative net margin of 1.69% and a positive return on equity of 15.74%. The firm's revenue was up .6% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.80 EPS. As a group, equities analysts forecast that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Insider Activity

In other news, EVP Joseph W. Laplume sold 800 shares of Charles River Laboratories International stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $157.60, for a total value of $126,080.00. Following the transaction, the executive vice president owned 24,116 shares of the company's stock, valued at $3,800,681.60. The trade was a 3.21% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. 1.30% of the stock is owned by corporate insiders.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).